Genmab

This trial is testing a new drug called epcoritamab in people with B-cell lymphoma that has come back or stopped responding to standard treatments. The main goals are to find a safe and effective dose, understand the side effects, and see how well the drug works to control the ca…

This study is testing a new drug called epcoritamab in Japanese adults with B-cell lymphoma that has come back or stopped responding to standard treatments. The first part of the study aims to find a safe and effective dose. The second part will test that dose, both alone and com…

This trial is testing whether a new injectable drug called epcoritamab works better than standard chemotherapy for people with an aggressive type of lymphoma that has come back or stopped responding to prior treatment. About 484 participants will be randomly assigned to receive e…

This is the first human trial testing a new cancer drug called GEN1047 in people with advanced solid tumors, including breast, ovarian, endometrial, and a type of lung cancer. The main goals are to find a safe dose and see if the drug helps shrink tumors. All 179 participants wil…

This trial is testing if a new drug called epcoritamab works better than standard chemotherapy for people with an aggressive type of lymphoma that has come back or stopped responding to prior treatments. Participants will be randomly assigned to receive either the new drug as an …

This study is testing a new drug called epcoritamab to see if it is safe and effective for people with certain hard-to-treat blood cancers. It is for adults with chronic lymphocytic leukemia (CLL) or Richter's syndrome that has come back or not responded to other treatments. The …

This early-stage trial is testing a new drug called GEN1286 in adults with advanced solid tumors that have spread or returned after other treatments. The main goals are to find a safe dose and see if the drug can help shrink tumors. The study is divided into two parts: first find…

This trial is testing the safety and early effectiveness of a new drug called epcoritamab, given alone or combined with standard treatments, for people with B-cell non-Hodgkin lymphoma. It includes over 500 participants with different types and stages of the disease, including ne…

This study is testing an experimental drug called acasunlimab (GEN1046) for people with advanced non-small cell lung cancer that has returned or stopped responding to standard immunotherapy. Researchers want to see if the drug works better when given alone or combined with anothe…

This early-stage trial is testing a new antibody drug called GEN1042 to see if it's safe and can help control advanced solid tumors. Researchers are giving GEN1042 alone or combined with another cancer drug (pembrolizumab) to about 350 adults with cancers like lung, colorectal, m…

This study is testing a new drug called acasunlimab, given alone or together with the cancer drug pembrolizumab, for people with advanced skin melanoma that has continued to grow despite prior immunotherapy. The main goal is to see if the treatment can shrink tumors and is safe. …

This trial is testing whether a new drug called acasunlimab, when combined with pembrolizumab, works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer. It is for patients whose cancer has spread, is PD-L1 positive, and has gotten wo…

This global study is testing whether a new drug called Rina-S works better than current standard chemotherapy for women with platinum-resistant ovarian cancer. All 530 participants will receive active treatment—either Rina-S or one of four approved chemotherapy drugs—with a 50/50…

This early-stage study is testing a new cancer drug called GEN1042 in Japanese patients with advanced solid tumors. Researchers will first give GEN1042 alone to check safety, then test it combined with other cancer drugs. The main goal is to find safe doses and see how the body h…

This study is testing two treatment approaches for elderly patients newly diagnosed with an aggressive type of lymphoma who cannot tolerate standard chemotherapy. Participants will receive either a single antibody drug or that same drug combined with another medication. The goal …

This early-stage trial is testing a new antibody drug called acasunlimab (GEN1046) for people with advanced solid tumors. The study first aims to find safe doses, then tests how well those doses work when given alone or combined with other cancer drugs. All 429 participants will …